TARS - Tarsus starts enrollment in TP-03 eye disease trial

Tarsus Pharmaceuticals (TARS) has commenced enrollment in Saturn-2, its trial evaluating the company’s novel investigational treatment, TP-03, in patients with Demodex blepharitis, an ocular disease that is characterized by inflammation of the eyelid margin.TP-03 is a topical ophthalmic formulation of lotilaner, an anti-parasitic agent designed to target and eradicate Demodex mites.The Saturn-2 trial, which is expected to enroll 418 patients, is a randomized, controlled, multicenter, double-masked trial studying the safety and efficacy of TP-03, lotilaner ophthalmic solution 0.25%.The trial’s primary endpoint is the proportion of patients achieving collarette cure, defined as 0 to 2 eyelashes with collarettes.

For further details see:

Tarsus starts enrollment in TP-03 eye disease trial